Bio-Rad Laboratories, Inc.
NYSE:BIOMedical - Devices
-$0.65 today
- Market cap
- $9.95B
- Beta
- 1.08
- P/E (TTM)
- 45.4
- EPS (TTM)
- $6.26
Volume 0.46M
Average 0.38M
BIO Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Bio-Rad Laboratories, Inc.NYSE: BIO
Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026
Cash & equivalents rises 40.0% from a year ago
Cash & equivalents stood at $517M at the end of Q2 FY2026, up 40.0% from a year earlier and up 1.9% from the prior quarter. Over 3 fiscal years it compounded at +7.0% a year.
Context
- Cash & equivalents amounted to 5.0% of total assets at the end of Q2 FY2026, up 1.4 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +40.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 531.8M USD
- Year-over-year change
- +9.0%
- 4-year CAGR
- +3.1%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 531.8M | +9.0% |
| FY2024 | 2024-12-31 | 488.1M | +20.9% |
| FY2023 | 2023-12-31 | 403.8M | -7.0% |
| FY2022 | 2022-12-31 | 434.22M | -7.8% |
| FY2021 | 2021-12-31 | 470.78M | — |
Cash & Equivalents vs competitors
How BIO compares with its peers on the latest reported figures
- BIO's Jun 2026 cash & equivalents of $517M is the 5th highest of the 11 companies compared; the peer median is $307.9M.
- Its year-over-year change of +40.0% is the 6th highest of 11, against a peer median of +39.6%.
- Cash & equivalents amounts to 5.0% of total assets for BIO, versus a peer median of 9.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $5.68B | +271.9% | -8.4% | 6.1% | |
| Sep 2026 | $5.46B | +175.5% | +4.9% | 4.8% | |
| Jul 2026 | $1.02B | +3.1% | +26.5% | 8.5% | |
| Jun 2026 | $606.78M | -14.4% | +2.6% | 20.6% | |
| Jun 2026 | $517M | +40.0% | +7.0% | 5.0% | |
| Sep 2026 | $350.04M | +141.5% | +13.6% | 13.3% | |
| Mar 2026 | $265.77M | +76.1% | +13.3% | 41.6% | |
| Sep 2026 | $193.8M | -31.3% | -34.2% | 11.3% | |
| Jun 2026 | $184.9M | +101.0% | -22.6% | 3.1% | |
| Jun 2026 | $70.09M | -74.0% | -30.0% | 11.6% | |
| Mar 2026 | $56.29M | -3.8% | -41.9% | 7.2% | |
| Peer median (excluding BIO) | $307.9M | +39.6% | -2.9% | 9.9% | |
Competitors are the stored peer set for BIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 470.78M | 434.22M | 403.8M | 488.1M | 531.8M |
| Short-term Investments | 399.14M | 1.36B | 1.2B | 1.18B | 1.01B |
| Net Receivables | 423.54M | 494.65M | 489M | 452.5M | 472.5M |
| Inventory | 572.24M | 719.32M | 780.5M | 760M | 740.7M |
| Other Current Assets | 15.65M | 29.16M | 31.7M | 30.7M | 13.8M |
| Total Current Assets | 1.99B | 3.16B | 3.05B | 3.03B | 2.91B |
| Property, Plant & Equipment (Net) | 716.44M | 679.55M | 723.7M | 688.6M | 709.9M |
| Goodwill | 347.3M | 406.5M | 413.6M | 410.5M | 579.8M |
| Intangible Assets | 253.9M | 332.1M | 320.5M | 293.6M | 174.3M |
| Long-term Investments | 14.39B | 8.83B | 7.7B | 4.84B | 6.1B |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 104.19M | 94.6M | 94.9M | 101.9M | 102.3M |
| Total Non-current Assets | 15.81B | 10.34B | 9.25B | 6.33B | 7.67B |
| Total Assets | 17.8B | 13.5B | 12.3B | 9.36B | 10.58B |
| Account Payables | 141.94M | 135.04M | 144.6M | 122.3M | 129M |
| Short-term Debt | 489K | 465K | 500K | 1.2M | 37.9M |
| Tax Payables | 46.3M | 32.43M | 35.8M | 31.2M | 36.6M |
| Deferred Revenue | 50.85M | 52.21M | 0 | 0 | 0 |
| Other Current Liabilities | 127.94M | 117.44M | 161.6M | 147.2M | 141.2M |
| Total Current Liabilities | 680.94M | 568.71M | 522.8M | 467.8M | 517M |
| Long-term Debt | 10.51M | 1.2B | 1.2B | 1.2B | 1.34B |
| Deferred Tax Liabilities | 3.06B | 1.77B | 1.48B | 818M | 1.06B |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 182.19M | 195.93M | 195M | 177.2M | 53.4M |
| Total Non-current Liabilities | 3.43B | 3.32B | 3.04B | 2.33B | 2.61B |
| Total Liabilities | 4.11B | 3.89B | 3.56B | 2.79B | 3.12B |
| Common Stock | 3K | 3K | 0 | 0 | 0 |
| Retained Earnings | 13.53B | 9.9B | 9.26B | 7.42B | 8.18B |
| Accumulated OCI | (175.55M) | (466.82M) | (336M) | (538.2M) | (189.1M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 13.69B | 9.62B | 8.74B | 6.57B | 7.45B |
| Total Debt | 223.38M | 1.39B | 1.41B | 1.37B | 1.53B |
| Net Debt | (247.41M) | 953.88M | 1B | 886.6M | 999.2M |
Bio-Rad Laboratories, Inc.
NYSE:BIO
Intrinsic Alpha fair value
Locked
Current Price
$370.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.